Overall survival according to mutational status in tumor and serum is shown in Figure 1A. There was no clinical or significant difference in risk of event between patients with a wild‐type tumor and those with a RAS/BRAF mutation in the tumor (P = 0.22), and the same was true as to DFS (P = 0.31). The gene discussed is BRAF; the disease is neoplasm.